Nasdaq

Showing 679 articles
Business

Reitar Logtech's Steady Fundamentals Clash with Market Pessimism: Is the 50% Sell-Off Overdone?

Despite a brutal 50% share price plunge over three months, Reitar Logtech Holdings (NASDAQ:RITR) exhibits underlying financial resilience. While its Return on Equity appears weak, the company's aggressive reinvestment strategy has fueled a remarkable 26% net income growth over five years, starkly outperforming its struggling industry. This analysis delves into the disconnect between short-term market sentiment and the firm's long-term operational engine.

Business

Private Equity Reaps Windfall as Elong Power's Market Value Soars

A staggering 2,313% surge in Elong Power Holding's (NASDAQ: ELPW) share price last week delivered a massive payoff for its largest shareholder group—private equity firms. With concentrated ownership and scant analyst coverage, the stock's dramatic move highlights both its potential and the risks inherent in such thinly followed names.

Business

Bassett Furniture Stock: A Value Play Amid Market Volatility?

Bassett Furniture Industries (NASDAQ: BSET) has seen significant price swings in recent months, drawing investor scrutiny. With a current trading price well below its calculated intrinsic value and a bullish earnings forecast, analysts are debating whether this small-cap furniture maker presents a timely buying opportunity.

Business

Itron's Meteoric Rise: How the Utility Tech Firm Outpaced the Market with 71% Gains

While index funds offer market-average returns, picking the right stock can yield significantly more. Itron, Inc. (NASDAQ: ITRI) has proven just that, delivering a 71% return to shareholders over the past three years—outperforming broader indices—as it transitioned to profitability. However, recent headwinds have tempered the rally, raising questions about its near-term trajectory.

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...